<DOC>
	<DOCNO>NCT01311947</DOCNO>
	<brief_summary>In order clarify association HBV mutation appear interferon therapy therapeutic effect , serial serum sample 100 HBeAg-positive CHB patient undergo peginterferon alfa-2a therapy collect analyzed mutation preS/S gene BCP-preC/C region , particularly deletion mutation . Furthermore , Real-Time PCR perform measure ratio wild-type HBV deletion mutant HBV end peginterferon alfa-2a therapy . Finally , statistical analysis do elucidate whether mutation preS/S gene BCP-preC/C region relation therapeutic effect peginterferon alfa-2a .</brief_summary>
	<brief_title>Hepatitis B Virus Mutants Therapeutic Effect Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B</brief_title>
	<detailed_description>Hepatitis B virus ( HBV ) infection serious worldwide health issue . Approximately 400 million people worldwide chronic hepatitis B ( CHB ) patient . Currently , two therapeutic method use treat CHB . One nucleos ( ) ide analogue , interferon alfa . Interferon alfa act mainly enhance immune system directly inhibit virus limited extent . It known mutation preS , S , basal core promoter , precore core gene associate increase risk HCC . However , remain clarified relation HBV mutation therapeutic response interferon treatment . In order clarify association HBV mutation appear interferon therapy therapeutic effect , serial serum sample 100 HBeAg-positive CHB patient undergo peginterferon alfa-2a therapy collect analyzed mutation preS/S gene BCP-preC/C region , particularly deletion mutation . Furthermore , Real-Time PCR perform measure ratio wild-type HBV deletion mutant HBV end peginterferon alfa-2a therapy . Finally , statistical analysis do elucidate whether mutation preS/S gene BCP-preC/C region relation therapeutic effect peginterferon alfa-2a .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>HBeAgpositive chronic hepatitis B patient Peginterferon therapy HBeAgnegative chronic hepatitis B patient HBeAgpositive chronic hepatitis B patient kinds therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Chronic hepatitis B</keyword>
	<keyword>Peginterferon alfa-2a</keyword>
</DOC>